Lantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8:00 a.m. Eastern Time
Lantheus Holdings (NASDAQ: LNTH) announced a conference call and webcast scheduled for May 4, 2023, at 8:00 a.m. ET to discuss its Q1 2023 financial and operating results.
Rhea-AI Summary
Lantheus Holdings (NASDAQ: LNTH) announced a conference call and webcast scheduled for May 4, 2023, at 8:00 a.m. ET to discuss its Q1 2023 financial and operating results. Participants can register online to access the call and are advised to register 15 minutes early to avoid delays. A replay will be available two hours post-webcast, archived for at least 30 days. With over 65 years in the field, Lantheus focuses on enhancing patient outcomes through diagnostics, radiotherapeutics, and AI solutions aimed at disease management. Headquartered in Massachusetts, the company also operates in New Jersey, Canada, and Sweden.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LNTH
The recorded move for LNTH in the trading session of this news was -1.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 4, 2023, to discuss its financial and operating results for the first quarter of 2023.
To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time.
A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days.
About Lantheus
With more than 65 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Senior Director, Corporate Communications
646-975-2533
media@lantheus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.